开发用于AML治疗的口服,强效和选择性CK1α降解剂
Lu Huang1,2, Lu Chen3, Lu Chen2
1Department of Cardiovascular Surgery, The First Affiliated Hospital of Anhui Medical University, 218 Jixi Road, Hefei 230022, China.
JACS Au
|November 29, 2024
概括
研究人员开发了针对CK1α的新型分子降解剂 (MGDs). 这些MGD在小鼠模型中显示出强烈的降解和有效性,为癌症治疗提供了新的治疗选择.
科学领域:
- 生物化学 生物化学
- 药用化学 医学化学
- 在瘤学瘤学.
背景情况:
- 分子降解剂 (MGDs) 通过桥接目标蛋白和E3结合酶来诱导向蛋白降解.
- 传统的分子通常是偶然发现的.
- 基于cereblon (CRBN) 的配体为MGD的发展提供了重新编程的潜力.
研究的目的:
- 通过CRBN依赖的扩散屏幕来识别针对必需蛋白质的基于CRBN的新型MGD.
- 为治疗应用开发强效和选择性的MGD.
主要方法:
- 进行了CRBN依赖的扩散选,以识别MGDs.
- 利用药用化学来优化化合物.
- 合成的口服活性衍生物具有改善的药理动力学特性.
- 在小鼠模型中评估了降解活性和体内疗效.
主要成果:
- 鉴定了dCK1α-1,一种强效和选择性的CK1α向MGD.
- 开发了dCK1α-2,一种口服活性衍生物,具有增强的药理动力学.
- 在小鼠模型中证明了dCK1α-2的明显降解活性和体内疗效.
- 展示了表型药物发现和CRBN联体库的实用性.
结论:
- 现型药物发现加速了治疗相关的MGDs的发展.
- dCK1α-1和dCK1α-2为具有功能性p53信号的癌症提供了新的治疗途径.
- 这些MGD作为研究CK1α在疾病中的作用的有价值的化学工具.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Drugs that Destabilize Microtubules
1.9K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
1.9K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
147
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
147
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K


